Amgen acquires stake in BeiGene to grow cancer drug business to China – STAT

Amgen is acquiring a premium stake in BeiGene (BGNE), one of the largest cancer-focused drug companies in China, for $2.7 billion as part of a broad commercial and drug development partnership, both companies announced Thursday.
The California-based biotech …

Click here to view the original article.